초록 ▼

The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. Th

The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1α, IL-1β and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of insulin resistance associated pathologies) and for treating IL-1 haplotype associated insulin resistance associated pathologies.

대표청구항 ▼

1. A method for determining whether a human subject is likely to have or is predisposed to developing insulin resistance comprising obtaining a nucleic acid sample from said human subject and detecting a haplotype comprising allele 1 of IL-1B (−511), allele 2 of IL-1A (+4845) and allele 2 of IL-1B (

1. A method for determining whether a human subject is likely to have or is predisposed to developing insulin resistance comprising obtaining a nucleic acid sample from said human subject and detecting a haplotype comprising allele 1 of IL-1B (−511), allele 2 of IL-1A (+4845) and allele 2 of IL-1B (+3954) in said sample, wherein a human subject who possesses the haplotype is more likely to have or is predisposed to developing insulin resistance when compared to a human subject who does not possess the haplotype. 2. The method of claim 1, wherein the insulin resistance is associated with type 2 diabetes or metabolic syndrome. 3. A method for determining whether a human subject is likely to have or is predisposed to expressing a decreased level of C-reactive protein comprising obtaining a nucleic acid sample from said human subject and detecting in said sample a B212 haplotype, wherein the B212 haplotype comprises allele 2 of IL-1B (−511), allele 1 of IL-1B (−1464) and allele 2 of IL-1B (−3737), wherein a human subject who possesses the B212 haplotype is likely to have or is predisposed to expressing a decreased level of C-reactive protein when compared to a human subject who does not possess the B212 haplotype. 4. The method of claim 3, wherein the human subject is Asian or of Asian descent. 5. The method of claim 3, wherein the human subject is Korean or of Korean descent. 6. The method of claim 3, wherein the human subject who possesses the B212 haplotype is likely to have or is predisposed to expressing an increased level of high density lipoprotein when compared to a human subject who does not possess the B212 haplotype. 7. The method of claim 3, wherein the human subject who possesses the B212 haplotype is likely to have or is predisposed to expressing a decreased level of low density lipoprotein when compared to a human subject who does not possess the B212 haplotype. 8. The method of claim 3, wherein the human subject who possesses the B212 haplotype is likely to have or is predisposed to expressing a decreased level of triglyceride when compared to a human subject who does not possess the B212 haplotype. 9. The method of claim 3, wherein the human subject who possesses the B212 haplotype is likely to have or is predisposed to a decreased risk of cardiovascular disorders or metabolic disorders when compared to a human subject who does not possess the B212 haplotype.